This article is a clinical guide which discusses the “state-of-the-art” usage of the classic monoamine oxidase inhibitor (MAOI) antidepressants (phenelzine, tranylcypromine, and isocarboxazid) in modern psychiatric practice. The guide is for all clinicians, including those who may not be experienced MAOI prescribers. It discusses indications, drug-drug interactions, side-effect management, and the safety of various augmentation strategies. There is a clear and broad consensus (more than 70 international expert endorsers), based on 6 decades of experience, for the recommendations herein exposited. They are based on empirical evidence and expert opinion—this guide is presented as a new specialist-consensus standard. The guide provides practical clinical advice, and is the basis for the rational use of these drugs, particularly because it improves and updates knowledge, and corrects the various misconceptions that have hitherto been prominent in the literature, partly due to insufficient knowledge of pharmacology. The guide suggests that MAOIs should always be considered in cases of treatment-resistant depression (including those melancholic in nature), and prior to electroconvulsive therapy—while taking into account of patient preference. In selected cases, they may be considered earlier in the treatment algorithm than has previously been customary, and should not be regarded as drugs of last resort; they may prove decisively effective when many other treatments have failed. The guide clarifies key points on the concomitant use of incorrectly proscribed drugs such as methylphenidate and some tricyclic antidepressants. It also illustrates the straightforward “bridging” methods that may be used to transition simply and safely from other antidepressants to MAOIs.

Field studies were conducted at the Pontotoc Ridge–Flatwoods Branch Experiment Station in Pontotoc, MS, in 2016 and 2017 to determine sweetpotato crop response to saflufenacil and rimsulfuron/thifensulfuron-methyl. Saflufenacil treatments consisted of a factorial of two rates (25 or 50 g ai ha–1) by three application timings [0, 3, or 6 wk before transplanting (WBP)]. Rimsulfuron/thifensulfuron-methyl treatments consisted of a factorial of two rates (18/18 or 35/35 g ai ha–1) by two application timings (3 or 6 WBP). A nontreated check was included for comparison. Saflufenacil resulted in as much as 20% stunting injury in 2016, but ≤4% crop injury in 2017. Compared to the nontreated check, saflufenacil did not reduce yield of any sweetpotato grade regardless of application rate or timing. Findings from this trial indicate that saflufenacil applied in pre-transplanting burndown and field preparation procedures did not have a negative impact on the subsequent sweetpotato crop and that the current plant-back interval (4 to 5 mo) may be excessive. Applications of rimsulfuron/thifensulfuron-methyl at 35/35 g ha–1 made 3 WBP resulted in significant crop injury but did not reduce yield of any sweetpotato grade. Findings from this trial suggest that rimsulfuron/thifensulfuron-methyl applications up to 35/35 g ha–1 applied at least 6 WBP and 18/18 g ha–1 applied at least 3 WBP had little impact on sweetpotato crop growth and may be a safe preplant burndown option.

This paper examines intra-day trading data from the inter-dealer broker market for U.S. Treasury securities and measures the degree of price pressure in the off-the-run Treasury market. As is well known, securities that would appear to be very close substitutes, i.e., on-the-run and off-the-run Treasury bonds, behave as if there is some degree of market segmentation. This is the first systematic study of the off-the-run Treasury note and bond market focused entirely on a price pressure effect using intra-day data. The paper analyzes price pressure through matched pairs of securities that differ only in liquidity.